Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962225 | 0.79 | MEN1 (0.36) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL8922080 | 0.77 | MEN1 (0.43) | MEN1KMT2ANLRP3KDM4EMAPT | |
| SCHEMBL21962348 | 0.77 | UGT2B17 (0.32) | UGT2B17MAPTALDH1A1HTTACHE | |
| SCHEMBL21962062 | 0.74 | KDM4E (0.38) | NLRP3KDM4EMAPT | |
| SCHEMBL22011027 | 0.72 | UGT2B17 (0.49) | MEN1KMT2AUGT2B17NLRP3MAPT | |
| SCHEMBL25033144 | 0.72 | UGT2B17 (0.49) | MEN1KMT2AUGT2B17NLRP3MAPT | |
| SCHEMBL22010660 | 0.72 | UGT2B17 (0.49) | MEN1KMT2AUGT2B17NLRP3MAPT | |
| SCHEMBL25842400 | 0.70 | NLRP3 (0.33) | NLRP3MAPTALDH1A1HTT | |
| SCHEMBL21962290 | 0.70 | GRIN2D (0.45) | MEN1KMT2ANLRP3MAPTALDH1A1 | |
| SCHEMBL21586529 | 0.70 | MAPT (0.43) | MEN1KMT2ANLRP3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3797/4885KMT2A 4479/4885UGT2B17 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.